Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotoclaro plus R-CHOP for newly diagnosed BCL2-positive aggressive B-cell lymphoma
ChiCTR2600131616Phase 2Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax in aggressive B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Complete remission rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sonrotoclax
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600131616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131616.